Durvalumab

Durvalumab
	Antigen-binding fragment of durvalumab (pale green) in complex with PD-L1 (pink). PDB: 5X8M.
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CD274
Clinical data
Trade names	Imfinzi
Other names	MEDI4736, MEDI-4736
AHFS/Drugs.com	Monograph
MedlinePlus	a617030
License data	US DailyMed: Durvalumab;
Pregnancy; category	AU: D;
Routes of; administration	Intravenous
ATC code	L01FF03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	1428935-60-7;
PubChem CID	249565666;
IUPHAR/BPS	7985;
DrugBank	DB11714;
ChemSpider	none;
UNII	28X28X9OKV;
KEGG	D10808;
Chemical and physical data
Formula	C6502H10018N1742O2024S42
Molar mass	146322.36 g·mol−1

Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1).

Durvalumab is an immune checkpoint inhibitor drug. It was approved in for medical use in the United States in May 2017, and in the European Union in September 2018.